Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

You may be eligible if

• Radiographic evidence of lymphadenopathy or lymphomatous lesions combined with clinical signs of Epstein-Barr virus lymphoproliferative disease (EBV LPD), such as fevers and lymphadenopathy
• following an organ transplant Persistent, progressive, or unresponsive disease despite decreased immunosuppression, chemotherapy, or radiation therapy EBV LPD must be of host origin
• At least 4 weeks
• Patients serologically hepatitis B and C positive may receive cytotoxic
• T- lymphocytes (CTL) from donors who are serologically positive for the same virus
• Must have an HLA identical or HLA haploidentical donor
• Exclusion
• hepatic dysfunction SGOT/SGPT less than 2.5 times upper limit of normal (unless liver metastases present)
• Bilirubin less than 2.0 mg/dL
• renal dysfunction
• Creatinine clearance at greater than 50 mL/min
• cardiac dysfunction
• neurologic dysfunction
• pulmonary dysfunction
• patients developing EBV LPD who have a donor origin lymphoma
• HIV-1 positive
• Not capable of undergoing leukapheresis